Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohort of the second arm in its phase one trial of AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, on Thursday.
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Windward Ltd - Tel Aviv, Israel-based maritime predictive.
TRADING UPDATES: Windward wins deal; Kodal progresses at Bougouni | Finance News shareprices.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from shareprices.com Daily Mail and Mail on Sunday newspapers.